


PHARMACEUTICAL 2021

Cryoport Inc. Rank 63 of 409







PHARMACEUTICAL 2021



Cryoport Inc. Rank 63 of 409



The relative strengths and weaknesses of Cryoport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cryoport Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Cryoport Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 438% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	147,157
Cost of Goods Sold	42,362
Intangible Assets	359,190
Liabilities, Current	35,020
Liabilities, Non-Current	12,437
Other Assets	16,022
Other Compr. Net Income	5,421
Other Expenses	-45
Other Liabilities	122,250
Other Net Income	-2,728
Property and Equipment	30,036
Research and Development	9,484
Revenues	78,696
Selling, General and Administrative Expense	56,860

Output Variable	Value in 1000 USD
Assets	552,405
Liabilities	169,707
Expenses	108,661
Stockholders Equity	382,698
Net Income	-32,693
Comprehensive Net Income	-29,982
Economic Capital Ratio	83%

